Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 85 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results Year ended 31 December 2025 Intermediate Bulk Finished Segments products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,612,354 4,900,444 5,255,619 11,768,417 – 11,768,417 Inter-segment sales 2,405,952 992,419 – 3,398,371 (3,398,371) – License fee income (note) – – 1,442,210 1,442,210 – 1,442,210 Segment revenue 4,018,306 5,892,863 6,697,829 16,608,998 (3,398,371) 13,210,627 Segment profit before research and development expenses 650,191 391,231 2,373,972 3,415,394 Research and development expenses (included in the measurement of segment profit) (217,753) (62,419) (640,876) (921,048) RESULT Segment profit 432,438 328,812 1,733,096 2,494,346 Share of results of an associate (51) Unallocated other income 207,414 Unallocated corporate expenses (153,328) Unallocated other gains and losses, net 50,922 Impairment losses under expected credit loss model, net (1,620) Finance costs (69,730) Profit before taxation 2,527,953